a public good project by the
Synthesis
Company
of California

© 2026

Christine A. White | doi.page

0 works0 citations0 h-index

Christine A. White

Queen's University(CA)

Publications by Year

Research Areas

Dialysis and Renal Disease Management, Chronic Kidney Disease and Diabetes, Renal and Vascular Pathologies, Religion, Society, and Development, Lymphoma Diagnosis and Treatment

Most-Cited Works

→ IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma(1997)1,692 cited
→ Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma(2002)649 cited
→ Cytokines, chemokines and growth factors in endometrium related to implantation(2005)554 cited
→ Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma(1998)520 cited
→ CKD: A Call for an Age-Adapted Definition(2019)349 cited
→ Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma(2003)290 cited

→ Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial(2002)266 cited

→ Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma(2000)234 cited

→ The Chemokines, CX3CL1, CCL14, and CCL4, Promote Human Trophoblast Migration at the Feto-Maternal Interface1(2006)203 cited

→ A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma(2005)200 cited